Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical mesalazine to prevent adenoma formation in rectal stumps or ileal pouches after colectomy for FAP or MAP
2018-003076-13Phase 3Completed
- Sponsor
- IPO Lisboa
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Salcrozine in Colonic Adenomatous Polyposis and familial adenomatous polyposis 2 (MAP), sponsored by IPO Lisboa. Primary endpoint: Number of adenomas >5 mm in rectal stump or ileal pouch. Started Jun 2019; status: completed.
02
Drugs
Salcrozine
03
Conditions
Colonic Adenomatous Polyposisfamilial adenomatous polyposis 2 (MAP)
Beyond the preview
Go deeper on 2018-003076-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003076-13.